BRIEF—AEON Biopharma set up, with Botox Therapeutic head as CEO

California-based Alphaeon Corp today announced today that it has named Marc Forth as president and chief executive of its newly-established, wholly-owned subsidiary, AEON Biopharma.

AEON Biopharma was established to independently pursue the rapidly growing, multi-billion-dollar, therapeutic toxin market. Therapeutic related applications represent greater than 60% of global neurotoxin segment revenues.

Mr Forth joins AEON Biopharma from Allergan, where he was senior vice president of neurosciences, urology and medical dermatology.

Mr Forth led, among other brands, Botox Therapeutic, an organization with annual revenues of approximately $2 billion.

Simone Blank, chairperson of Alphaeon, said: "Marc's joining AEON Biopharma represents a major milestone for the company, as we move towards filing an Investigative New Drug Application (IND) for the first therapeutic indication of our 900 kDa purified botulinum toxin type A complex.”